OUR LEADERSHIP TEAM

CEO - Richard Craig

Mr. Craig is the founder of Global Eco Products, LLC. Global Eco Products, LLC (GEP) is the global distributor for products and technologies created by Dr. Rique Ford at International Eco Fuels, Inc. (IEFI). GEP works very closely with IEFI in the creation, research and development, certification testing and then the real world testing and data collection of many new technologies and products.

One of Mr. Craig's current priorities is to oversee the day to day operations, certification, and launch of the Eco-Proven technology. Eco-Proven is a NEW platform technology from which many “All Natural - Non Toxic - Alcohol Free” human, animal and plant health mitigation strategies against viral and bacterial pathogens are being developed.

Previously, he served as General Manager and Global Director of Research and Development for International Eco-Fuels, Inc., positions that he still holds. As GM, Mr. Craig managed the launch of Eco-Fuel Saver into the Canadian and international markets. As a result, Eco-Fuel Saver was recognized by Canada’s largest national automotive parts and accessories supplier, Canadian Tire, as a national number #1 seller and “Best in Class”. He was responsible for creating retail and commercial opportunities and working to set up sales reps and authorized company distributors. He coordinated all technical and certified testing in certified labs within Canada and the US as well as all onsite company testing for clients.

Prior to these endeavours, Mr. Craig owned several successful agricultural and horticultural companies and functioned as CEO and President, actively managing day to day operations in those multi-state organizations. He holds a BA of Science in Agricultural Education from The Ohio State University with special emphasis in Physical Science, Plant Science and Horticulture.

Director of Technology Development & Certification Dr. Eric Weber

Dr. Weber earned a Bachelor of Science from the University of California, Los Angeles, and a Ph.D. in Molecular and Cell Biology from the University of Arizona. Following his postdoctoral training, he worked for several years as a senior scientist in the animal healthcare industry.

In 2012, he founded Endolytics. Endolytics is a contract research lab that supports drug development, for both human and animal health, with pre-clinical endocrine bioanalytics and in-vitro endocrine study capabilities. Dr. Weber has been instrumental in working with Colorado State University stakeholders to put in place licensing agreements, master research and development agreements and pricing for a University based contract lab with a unique business model of leveraging the capabilities of a University lab to support drug development within the private sector.

Dr. Weber oversees all aspects of daily operations including business

development, contracts, project management and accounting at Endolytics. Other key responsibilities include providing analytical oversight for all assays performed in both FDA-regulated and non-regulated studies, overseeing and directing development of new assays, establish and managing key accounts within the pharmaceutical industry in the preclinical endocrinology space and establishing strategic partnerships with CRO’s and small and midsized pharmaceutical companies focusing on both human and animal health.

In addition to his work at Endolytics, Dr. Weber has played an active role in designing the antimicrobial studies carried out with the EcoProven technology.

Director of Government & Corporate Relations Dennis Taylor

Mr. Taylor holds an MS in Biochemistry from the University of Bridgeport and an MBA from the University of New Haven. Mr. Taylor is a career professional that worked at Bristol-Myers Squibb and Pfizer for 23 years, specializing in infectious disease drug discovery and advance development. Mr. Taylor then transitioned into vaccine development, in both privately funded organizations and the Department of Defense/DHHS.

Mr. Taylor spent 7+ years as the Program Manager (contractor) with The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), managing pre-clinical studies. This work resulted in a significant step in the development of the first FDA-approved vaccine for the Ebola Zaire virus. The U.S. Food and Drug Administration (FDA) approved Ervebo, in December 2019. USAMRIID worked with Merck and the Defense Threat Reduction Agency (DTRA) to test the vaccine in non-human primate studies.

While at Bristol-Myers Squibb, Mr. Taylor authored 3 publications:

Publication in Bio Organic and Medicinal Chemistry Letters: Mar 25, 2005 - Novel Analogs of Linezolid Antiviral Res: Dec 1, 2000

- Antiviral Efficacy of Lobucavir Antimicrobal Agents Chemotheraphy. Mar 1, 1999

- Efficacy of Carbocyclic 2'-deoxyguanosine nucleoside in the

woodchuck model of hepatitis B virus infection.

Director of Business Development Richard Cormier

As Director of Business Development, Mr. Cormier seeks

to identify strategic markets and relationships to bring our

new EcoProven technology products to market.

Richard has had a diversified and successful 36-year

career in sales and business development.

He has held multiple regional and national marketing and sales

positions. He has been a sales leader for a building products manufacturing company, a technical rep for new tech construction materials, and a consultant for new technology business development. His projects and experience have included projects in Canada, the United States, Australia, Europe and the Middle East.

During the last 17 years, he has focused on new technology development. He has lead several companies’ technologies into and through their initial launch and helped them develop their short term and long term marketing and sales strategies. He has accumulated

experience in testing, proof of concept, certification standards and testing, performance monitoring, technical and marketing documentation, presentations, websites, business development strategies, technical support and training, and team building. He has project experience in the construction, agriculture, trucks and mobile equipment, alternative health treatments, emissions reduction, water purification and nanotechnology industries.

In recent years, he has drawn from his accumulated business development experience to guide and support small “new tech” companies to their next level of market acceptance and growth.

REDEFINING THE FUTURE OF HUMAN HEALTH